Risk factor
High price volatility
Poor trading liquidity
Considerable default risk
Profitability factor
Favourable analyst view
Greatly overvalued vs peers
Very low or no dividends
Risk / Profitability
Risk: Considerable
Profitability: Modest
Risk factor
High price volatility
Poor trading liquidity
Considerable default risk
Profitability factor
Favourable analyst view
Greatly overvalued vs peers
Very low or no dividends
$ 18.28
About
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b...
About
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective...